The conclusion of the ADC agreement remains subject to the necessary regulatory approvals and compliance with other closing conditions. Genmab is a publicly traded international biotechnology company specializing in the development and development of differentiated antibody drugs for the treatment of cancer. Founded in 1999, the company is the creator of the following authorized antibodies: DARZALEX® (Daratumumab, in agreement with Janssen Biotech, Inc.) for the treatment of certain indications for multiple myeloma in regions such as the United States, Europe and Japan, kesimpta® (subcutaneous ofatumumab, in agreement with Novartis AG), for the treatment of adults with forms of multiple sclerosis in the United States and TEPEZZA® (teprotumumab, as part of an agreement with Roche to sublicense Horizon Therapeutics plc) for the treatment of thyroid disease in the United States A subcutaneous formulation of daratumumab, known as DARZALEX FASPRO™ (Daratumumab and Hyaluronidase-fihj) in the United States, has been approved in the United States and Europe for the treatment of adult patients with certain indications for multiple myeloma. The first genmab-approved treatment, Arzerra® (ofatumumab, in agreement with Novartis AG), authorized for the treatment of certain indications for chronic lymphatic leukemia, is available in Japan and is also available in other areas through compassionate use or oncology access programs. Daratumumab is in Janssen`s clinical development for the treatment of additional indications for multiple myeloma, other blood cancers and amyloidosis. Genmab also has a large clinical and preclinical pipeline. The technological basis of genmab consists of validated and proprietary antibody technologies of the next generation – the DuoBody®Plattform for the production of bi-specific antibodies, the HexaBody®plattform platform that produces antibodies optimized for efficient function, the HexElect platform® which combines two co-dependent HexaBody molecules to introduce selectivity while maximizing therapeutic power, and the DuoHexaBody platform® which provides potential efficacy up to Pepoid antibodies improved by Hexameriza. tion. The company intends to use these technologies to create opportunities for total co-ownership or co-ownership of future products. Genmab has alliances with leading pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark, with locations in Utrecht, the Netherlands, Princeton, New Jersey, USA and Tokyo, Japan.
17.1 Aberdeen Drilling Consultants will not conduct illegal activities on behalf of the customer. Any such requirement voids the contract and any agreement with respect to the service and Aberdeen Drilling Consultants is entitled to recover all of its costs and expenses. . . .